| References |
|
|
Brossart P
(2002)
Dendritic cells in vaccination therapies of malignant diseases.
Transfusion and Apheresis Science
27:
183–186.
|
|
|
Choi MJ,
Kim JH and
Maibach HI
(2006)
Topical DNA vaccination with DNA/lipid based complex.
Current Drug Delivery
3:
37–45.
|
|
|
Gattinoni L,
Klebanoff CA,
Palmer DC et al.
(2005)
Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells.
The Journal of Clinical Investigation
115:
1616–1626.
|
|
|
Lowy DR and
Schiller JT
(2006)
Prophylactic human papillomavirus vaccines.
The Journal of Clinical Investigation
116:
1167–1173.
|
|
|
Marshall JL,
Gulley JL,
Arlen PM et al.
(2005)
Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte–macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas.
Journal of Clinical Oncology
23:
720–731.
|
|
|
Matzinger P
(1994)
Tolerance, danger, and the extended family.
Annual Review of Immunology
12:
991–1045.
|
|
|
McCarthy EF
(2006)
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas.
Iowa Orthopaedic Journal
26:
154–158.
|
|
|
McKee MD,
Roszkowski JJ and
Nishimura MI
(2005)
T cell avidity and tumor recognition: implications and therapeutic strategies.
Journal of Translational Medicine
3:
35.
|
|
|
Nagorsen D and
Thiel E
(2006)
Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.
Clinical Cancer Research
12:
3064–3069.
|
|
|
Phan GQ,
Touloukian CE,
Yang JC et al.
(2003)
Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens.
Journal of Immunotherapy
26:
349–356.
|
|
|
Querec T,
Bennouna S,
Alkan S et al.
(2006)
Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity.
The Journal of Experimental Medicine
203:
413–424.
|
|
|
other
Rosenberg SA (1986) Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2. Important Advances in Oncology 55–91.
|
|
|
Rosenberg SA
(2001)
Progress in human tumour immunology and immunotherapy.
Nature
411:
380–384.
|
|
|
Rosenberg SA,
Yang JC,
Topalian SL et al.
(1994)
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2.
The Journal of the American Medical Association
271:
907–913.
|
|
|
Salem ML,
Gillanders WE,
Kadima AN et al.
(2006)
Novel non-viral delivery approaches for IL-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity.
Journal of Interferon and Cytokine Research
26(9):
593–608.
|
|
|
Scallon BJ,
Snyder LA,
Anderson GM et al.
(2006)
A review of antibody therapeutics and antibody-related technologies for oncology.
Journal of Immunotherapy
29:
351–364.
|
|
|
Seya T,
Akazawa T,
Tsujita T and
Matsumoto M
(2006)
Role of Toll-like receptors in adjuvant-augmented immune therapies.
Evidence-Based Complementary and Alternative Medicine
3:
31–38; discussion 133–137.
|
|
|
Shackleton M,
Davis ID,
Hopkins W et al.
(2004)
The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand.
Cancer Immunity
4:
9.
|
|
|
Speiser DE,
Lienard D,
Rufer N et al.
(2005)
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.
The Journal of Clinical Investigation
115:
739–746.
|
|
|
Velardi A,
Ruggeri L,
Capanni M et al.
(2004)
Immunotherapy with alloreactive natural killer cells in haploidentical haematopoietic transplantation.
The Hematology Journal
5(Suppl. 3):
s87–s90.
|
|
|
Vermorken JB,
Claessen AM,
van Tinteren H et al.
(1999)
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial.
Lancet
353:
345–350.
|
|
|
Vuckovic S,
Clark GJ and
Hart DN
(2002)
Growth factors, cytokines and dendritic cell development.
Current Pharmaceutical Design
8:
405–418.
|
| Further Reading |
|
|
Kirkwood JM,
Moschos S and
Wang W
(2006)
Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
Clinical Cancer Research
12:
2331s–2336s.
|
|
|
Okamoto M and
Sato M
(2003)
Toll-like receptor signaling in anti-cancer immunity.
The Journal of Medical Investigation
50:
9–24.
|
|
|
Smith KJ,
Hamza S and
Skelton H
(2003)
The imidazoquinolines and their place in the therapy of cutaneous disease.
Expert Opinion on Pharmacotherapy
4:
1105–11191105-1119.
|
|
|
Tishler M and
Shoenfeld Y
(2006)
BCG immunotherapy – from pathophysiology to clinical practice.
Expert Opinion on Drug Safety
5:
225–229.
|
